Mikhail V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, RUS. Dr. Misha V. Blagosklonny subsequently
Immigrated to the USA, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical themes, suchas targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last writer for a clinical phase I/II
Trial paper.
 
After authoring seven papers within the period of a brief yet resulting
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to cooperate with Tito Fojo. Together, they
Published 26 papers. In addition, Dr. Misha Blagosklonny published dozens of experimental research papers and theoretical articles as lead
Author. The abovementioned sole-author papers
Mentioned two important topics.
The first of these focused on selectively killing cancer
Cells with deregulated cell cycle or drug resistance via
Confirming their resistance. The outcomes and underlying
Concept were so revolutionary that they were improperly cited by
Other scientists as “reversal of resistance, ” even though the publication was
Titled, “Exploiting of drug resistance instead of its reversal. ” One great
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint publication in 2001.
 
The second topic throughout Dr. Blagosklonny’s sole-author articles
Is a research method to produce knowledge by
Bringing a few facts together from seemingly irrelevant areas.
This results in new notions with testable forecasts, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Notion was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as supported by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Significant result discovered by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exceptionally well-tolerated
Anti-aging medicine, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny recognition for
“connecting dots that others cannot even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He agreed to assume responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before accepting another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) via
Inhibiting body aging — in other words, “preventing cancer
Via staying young. ” His lab closely worked together with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This resulted in the discovery of extra anti-aging
Drugs besides rapamycin. The cell culture studies were
Accompanied by studies in mice, including several models such as
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence via rapamycin as well as other mTOR inhibitors, life
Extension and cancer cure in mice, and combinations of anti-
Aging medicines to be taken by humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.